Session » Rheumatoid Arthritis - Clinical Aspects IV: Comorbidities in Rheumatoid Arthritis

Meeting: 2013 ACR/ARHP Annual Meeting

Abstract Number: 2680

Risk of Subsequent Infection among Rheumatoid Arthritis Patients Using Biologics

Abstract Number: 2681

Reduced Fertility In Women With Rheumatoid Arthritis: Influence Of Disease Activity and Medication Use

Abstract Number: 2682

Incidence Trends and Predictors Of Orthopedic Surgery In Patients With Rheumatoid Arthritis – Results From a Well Defined Population

Abstract Number: 2683

Application Of a Multi-Biomarker Disease Activity (Vectra^® DA) Score For Assessing Rheumatoid Arthritis Patients With Fibromyalgia Or Low C-Reactive Protein

Abstract Number: 2684

Impact Of Anti-Rheumatic Treatment On Immunogenicity Of Pandemic H1N1 Influenza Vaccine In Patients With Arthritis

Abstract Number: 2685

Anti-Peptidylarginine Deiminase 3/4 Cross-Reactive Antibodies Are Associated With Radiographic Interstitial Lung Disease In Rheumatoid Arthritis, An Effect Potentiated By Smoking

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.